HR
CRL icon

Howe & Rusling’s Charles River Laboratories CRL Stock Holding History

Howe & Rusling’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16
Closed -$3K – 478
2022
Q3 		$3K Buy
+16
New +$3.45K ﹤0.01% 773
2022
Q2 		– Sell
-19
Closed -$5K – 1077
2022
Q1 		$5K Hold
19
– – ﹤0.01% 640
2021
Q4 		$7K Hold
19
– – ﹤0.01% 590
2021
Q3 		$8K Hold
19
– – ﹤0.01% 541
2021
Q2 		$7K Hold
19
– – ﹤0.01% 539
2021
Q1 		$6K Sell
19
-3
-14% -$834 ﹤0.01% 567
2020
Q4 		$5K Hold
22
– – ﹤0.01% 601
2020
Q3 		$5K Hold
22
– – ﹤0.01% 536
2020
Q2 		$4K Buy
+22
New +$3.51K ﹤0.01% 556

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Howe & Rusling's CRL Position: Q4 2022 in Review

Howe & Rusling sold out of Charles River Laboratories (CRL) in Q4 2022, closing a stake of 16 shares — an estimated $3K sold.

Howe & Rusling first reported a position in CRL in Q2 2020 and held it in 9 quarters. The position peaked at $8K in Q3 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

  • Howe & Rusling reported no remaining Charles River Laboratories position as of Q4 2022 after selling out during the quarter.
  • Howe & Rusling sold 16 Charles River Laboratories shares in Q4 2022, an estimated $3K.
  • Howe & Rusling first reported a position in Charles River Laboratories in Q2 2020 and held it in 9 quarters.
  • Howe & Rusling's Charles River Laboratories position peaked at $8K in Q3 2021.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.